Enzon Pharmaceuticals, Inc. financial data

Symbol
ENZN on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
20 Commerce Drive, Suite 135, Cranford, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ENZON PHARMACEUTICAL INC (to 12/10/2002), ENZON INC (to 12/9/2002)
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 6.15K %
Return On Equity 49.7 % +416%
Return On Assets 3.18 % +396%
Operating Margin -4K % -10.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.2M shares 0%
Common Stock, Shares, Outstanding 74.2M shares 0%
Entity Public Float 7.59M USD -35.5%
Common Stock, Value, Issued 742K USD 0%
Weighted Average Number of Shares Outstanding, Basic 74.2M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 74.2M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Operating Income (Loss) -1.09M USD -6.37%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.38M USD +1838%
Income Tax Expense (Benefit) -120K USD +48.1%
Net Income (Loss) Attributable to Parent 1.5M USD +395%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46M USD +0.24%
Other Assets, Current 481K USD +26.6%
Assets, Current 46.5M USD +0.46%
Deferred Income Tax Assets, Net 360K USD +51.3%
Assets 46.8M USD +0.72%
Accounts Payable, Current 331K USD 0%
Accrued Liabilities, Current 190K USD +147%
Liabilities, Current 521K USD +27.7%
Retained Earnings (Accumulated Deficit) -70.4M USD +2.08%
Stockholders' Equity Attributable to Parent 3.29M USD +7.19%
Liabilities and Equity 46.8M USD +0.72%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 251K USD +47.6%
Net Cash Provided by (Used in) Financing Activities -1.28M USD 0%
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 74.2M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.02M USD +7.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 46M USD +0.24%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 34.1M USD -5.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 34.4M USD -5.44%
Deferred Income Tax Expense (Benefit) -122K USD +97.2%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) -117K USD +22.5%
Current Income Tax Expense (Benefit) 1K USD -50%
Preferred Stock, Shares Authorized 2.96M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Current Federal Tax Expense (Benefit) 0 USD
Share-based Payment Arrangement, Expense 0 USD
Deferred State and Local Income Tax Expense (Benefit) -40K USD +21.6%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%